20481-33-8

Usage

Uses

Used in Pharmaceutical Industry:
DIETHYL 2-[[(1,3-DIMETHYL-1H-PYRAZOL-5-YL)AMINO]METHYLIDENE]MALONATE is used as a building block for synthesizing various organic compounds, contributing to the development of new pharmaceuticals and therapeutic agents. Its unique chemical structure allows for the creation of diverse molecules with potential medicinal properties.
Used in Organic Synthesis:
In the field of organic synthesis, DIETHYL 2-[[(1,3-DIMETHYL-1H-PYRAZOL-5-YL)AMINO]METHYLIDENE]MALONATE is used as a key intermediate for the preparation of complex organic molecules. Its malonate ester and pyrazole ring structures provide a versatile platform for further chemical reactions and modifications, enabling the synthesis of a wide range of organic compounds with various applications.
Used in Research and Development:
DIETHYL 2-[[(1,3-DIMETHYL-1H-PYRAZOL-5-YL)AMINO]METHYLIDENE]MALONATE is also used in research and development settings to explore its chemical properties and potential applications. Scientists and researchers utilize DIETHYL 2-[[(1,3-DIMETHYL-1H-PYRAZOL-5-YL)AMINO]METHYLIDENE]MALONATE to study its reactivity, stability, and interactions with other molecules, which can lead to the discovery of new chemical reactions and applications in various industries.

InChI:InChI=1/C13H19N3O4/c1-5-19-12(17)10(13(18)20-6-2)8-14-11-7-9(3)15-16(11)4/h7-8,14H,5-6H2,1-4H3

Upstream product

• 3524-32-1 5-Amino-1,3-dimethylpyrazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 20481-15-6 ethyl 4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxylate 
• 175201-95-3 4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 
• 175201-94-2 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 175201-98-6 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 389058-62-2 4-[(3-methoxyphenyl)amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 389058-61-1 1,3-dimethyl-4-[3-(pyrrolidin-3-yloxy)-phenylamino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide 
• 389058-54-2 3-[3-(5-carbamoyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-ylamino)-phenoxy]-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and characterization of new 1H-pyrazolo[3,4-b]pyridine phosphoramidate derivatives

Twelve new 1H-pyrazolo[3,4-b]pyridine phosphoramidate derivatives were synthesized under mild conditions by nucleophilic aromatic substitution reaction of aminoalkylphosphoramidates over 4-Cl substituted pyrazolo[3,4-b]pyridine in good yields. The new com

Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB2 cannabinoid receptor partial agonists

Recent developments indicate that CB2 receptor ligands have the potential to become therapeutically important. To explore this potential, it is necessary to develop compounds with high affinity for the CB2 receptor. Very recently, we

SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV.

PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula 1: can be useful in the treatment, prevention, inhibiti

PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formura 1: can be useful in the treatment, prevention, inhibitio

New orally active PDE4 inhibitors with therapeutic potential

Structural optimization of pyrazolopyridine derivative 2, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was carried out successfully. The process of discovery of new orally active PDE4 inhibitors, which

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

New orally active PDE4 inhibitors with therapeutic potential

The design, synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridine derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhib